The first oral session in the acute myeloid leukemia (AML) translational research track of June 15, was given by Eliza Yankova, from the University of Cambridge, who presented collaborative studies done together with Storm Therapeutics Ltd. outlining pharmacological inhibition of METTL1 as a therapeutic strategy in AML treatment.
Myeloproliferative neoplasms (MPNs) can only be cured, to date, using allogeneic stem cell transplantation which, in turn, only works for up to 20% of patients. As calreticulin (CALR) frameshift mutations are the second most common cause of MPNs, targeting this endoplasmic reticulum resident protein is one of the strategies emerging at the forefront of hematological malignancies research.
Throughout the 2024 annual congress of the European Association for the Study of the Liver (EASL), held in Milan last week, almost all basic tracks included some reference to epigenetics, or changes to the chromatin that affect how accessible a gene is to the transcription machinery.
The ongoing European Association for the Study of the Liver 2024 congress in Milan opened yesterday with several presentations on cell plasticity and its role in liver function and regeneration in chronic liver disease situations.
After many years of testing different monoclonal antibodies against amyloid-β protein, the results obtained are far from being outstanding, and the control of the progression and symptoms of Alzheimer’s disease (AD) remains elusive. At the recent AD/PD 2024 conference held in Lisbon, new non-anti-amyloidogenic strategies in the starting line against AD were discussed. Professor Einar Sigurdsson from New York University gave a presentation entitled, “Single domain antibodies for therapy and diagnosis of synucleinopathies and tauopathies.”
After many years of testing different monoclonal antibodies against amyloid-β protein, the results obtained are far from being outstanding, and the control of the progression and symptoms of Alzheimer’s disease (AD) remains elusive. At the recent AD/PD 2024 conference held in Lisbon, new non-anti-amyloidogenic strategies in the starting line against AD were discussed. Professor Einar Sigurdsson from New York University gave a presentation entitled, “Single domain antibodies for therapy and diagnosis of synucleinopathies and tauopathies.”
Advances in understanding the processes underlying brain neurodegeneration have allowed lots of new treatment and prevention strategies to begin to flourish. Several presentations at the 2024 Alzheimer’s & Parkinson’s Diseases Conference recently held in Lisbon reflect that eyes are now on some individuals who, despite showing pathological signs in their brains, stay cognitively healthy across several endogenous mechanisms of resilience.
The third day of the AD/PD 2024 conference in Lisbon started with a plenary lecture given by Professor Howard Fillit entitled, “Translating the biology of aging into new therapeutics for Alzheimer’s disease.” Fillit, a recognized neuroscientist and geriatrician, and co-founder of the Alzheimer’s Drug Discovery Foundation (ADDF), pointed to the geroscience hypothesis which postulates that targeting aging processes may result in preventive and therapeutic options for diseases of old age, including Alzheimer’s disease (AD).
At the 2024 Alzheimer’s & Parkinson’s Diseases Conference this week, Michel Goedert from the MRC Laboratory of Molecular Biology in Cambridge gave the Donald L. Price Memorial Plenary Lecture entitled, “Cryo-EM structures of disease filaments from human brains.” Donald Price was particularly well-known for his work on plaques and tangles in nonhuman aged primate brains and for the development of several animal models of neurodegenerative diseases.
Researchers from the La Jolla Institute for Immunology (LJI) and collaborators have presented a new platform to identify and validate neoantigens that would otherwise escape traditional routine sampling methods. The project, which they describe in an article published on Feb. 28, 2024, in Science Translational Medicine, started after discussions at the beginning of a cancer vaccine program between teams at UCSD Moores Cancer Center (MCC) and LJI.
